TWP-102

Primary objectives: a. To evaluate the safety and tolerability of TWP-102 injection in subjects with advanced malignant tumors; b. To determine the maximum tolerated dose (MTD) of TWP-102 injection in subjects with advanced malignant tumors by the incidence of dose-limiting toxicity (DLT); Secondary objectives: a. To evaluate the pharmacokinetic characteristics of TWP-102 injection in subjects with advanced malignant tumors; b. To evaluate the pharmacodynamic characteristics of TWP-102 injection in subjects with advanced malignant tumors; c. To evaluate the immunogenicity of TWP-102 injection in subjects with advanced malignant tumors; d. To evaluate the preliminary antitumor activity of TWP-102 injection in subjects with advanced solid tumors using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; and to evaluate the preliminary antitumor activity of TWP-102 injection in subjects with non-Hodgkin's lymphoma using the 2014 version of the Lugano evaluation criteria. Exploratory purpose: a. To explore the preliminary anti-tumor activity of TWP-102 injection in subjects with advanced solid tumors using the immunotherapy efficacy evaluation criteria in solid tumors (iRECIST) standard; b. To explore biomarkers for detecting the efficacy of TWP-102 injection in the treatment of advanced malignant tumors.